Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases

• US 20050143363A1
• Filed: 09/29/2003
• Published: 06/30/2005
• Est. Priority Date: 09/29/2002
• Status: Abandoned Application

• Current Assignee: Surmodics Incorporated
• Original Assignee: InnoRx, Inc. (Surmodics Incorporated)
• Inventors: De Juan, Eugene, Varner, Signe
• Application Number:
  US10/507,461
• Publication Number:
  US 20050143363A1
• Time in Patent Office: Days
• US Class Current: 514/179
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Featured is a methodology for administering a therapeutic medium to the posterior segment of an eye including instilling or disposing the therapeutic medium sub-retinally. In particular embodiments, the therapeutic medium is disposed in a sub retinal space. Such instillation being accomplished by one of injection or implantation of the therapeutic medium sub-retinally or the sub-retinal space. In other aspects, the methodology further includes forming a limited retinal detachment so as to define the sub-retinal space as well as methods for treating an eye by sub-retinally administering a therapeutic medium.

Claims

1. A method for administering a therapeutic medium to a posterior segment of an eye, the method comprising the step of:

instilling the therapeutic medium sub-retinally.

2. The administering method of claim 1, wherein said step of instilling includes localizing the action of the therapeutic medium at the choroid and the retina and minimizing action at other tissues of the eye.

3. The administering method of claim 1, wherein the therapeutic medium being administered is one of a drug, medicament, antiproliferative, neuroprotective, steroidal anti-inflammatory, non-sterodial anti-inflammatory, growth factor, neurotropic factor, antiangiogenic, thromobolytic or a gene.

4. The administering method of claim 3, wherein the steroidal anti-inflammatrory is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

5. The administering method of claim 1, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

6. The administering method of claim 1, wherein said step of instilling includes forming a depot of a drug between the choroid and the retina.

7. The administering method of claim 1, wherein said step of instilling includes one of injecting or implanting the therapeutic medium sub-retinally.

8. The administering method of claim 7, wherein said step of instilling includes injecting a solution including the therapeutic medium between the choroid and the retina.

9. The administering method of claim 1, wherein said step of instilling includes instilling the therapeutic medium in a sub-retinal space.

10. The administering method of claim 1, wherein the therapeutic medium comprises a sustained release device and wherein said step of instilling includes implanting the sustained release device in a sub-retinal space.

11. The administering method of claim 1, wherein said step of instilling includes:

creating a localized retinal detachment to define a sub-retinal space; and

disposing the therapeutic medium in the sub-retinal space formed by the localized retinal detachment.

12. The administering method of claim 11, wherein said disposing includes one of injecting or implanting the therapeutic medium in the sub-retinal space formed by the retinal detachment.

13. The administering method of claim 12, wherein said injecting includes injecting a solution including the therapeutic medium in the sub-retinal space.

14. The administering method of claim 12, wherein the therapeutic medium comprises a sustained release device and wherein said step of implanting includes implanting the sustained release device in the sub-retinal space.

15. The administering method of claim 14, wherein the sustained release device is configured to provide a sustained sub-retinal release of the therapeutic medium.

16. The administering method of claim 10, wherein the sustained release device is configured to provide a sustained sub-retinal release of the therapeutic medium.

17. The administering method of claim 15, wherein the therapeutic medium is one of a drug, medicament, antiproliferative, neuroprotective, steroidal anti-inflammatory, non-sterodial anti-inflammatory, growth factor, neurotropic factor, antiangiogenic, thromobolytic or a gene.

18. The administering method of claim 17, wherein the steroidal anti-inflammatory is selected from the group consisting of triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone, and derivatives thereof.

19. The administering method of claim 11, wherein a disease state to be treated is selected from the group consisting of ocular neovascularization, ocular inflammation and retinal degeneration.

28. The administering method of claim 1, further comprising the step of controllably releasing over time the sub-retinally instilled therapeutic medium.

20. A method for treating an eye, comprising the step of:

administering a therapeutic medium to a posterior segment of an eye sub-retinally.

25. The eye treatment method of claim 20, wherein said step of administering includes:

forming a sub-retinal space; and

disposing the therapeutic medium in the sub-retinal space.

27. The eye treatment method of claim 20, further comprising the step of controllably releasing the over time the sub-retinally administered therapeutic medium.

21-24. -24. (canceled)

28A. A. (canceled)

29. A method for administering a steroid to a posterior segment of an eye, the method comprising the step of:

instilling the steroid sub-retinally.

30. The administering method of claim 29, wherein said step of instilling includes localizing the action of the steroid at the choroid and the retina and minimizing action at other tissues of the eye.

31-44. -44. (canceled)

45. A method for treating an eye, comprising the step of:

administering a steroid to a posterior segment of an eye sub-retinally.

46. The eye treatment method of claim 45, wherein said step of administering sub-retinally includes forming a depot of a drug between the choroid and the retina.

47-57. -57. (canceled)